"It's a miracle that people are living so much longer, but longer life expectancies alone are not enough. People should be able to enjoy their later years - and we need a breakthrough in Alzheimer's to fulfill that."
ReceptorPharma is happy and proud to announce that we now officially can call ourselves an innovative startup. We were recently awarded the Swedish governmental agency Vinnova’s Innovative Startups phase I grant. Thanks to these funds we are now able to fast-track our business- and drug development more efficiently. Thank you for your financial support and belief in our business Vinnova!
The world is changing. We are getting older and older. But there is a huge price for our extended lifespans. As we get older, the risk of suffering from dementia increases dramatically. Every 3 seconds, someone in the world develops dementia. There were an estimated 47 million people around the world living with dementia in 2015. This number is thought to double every 20 years, reaching 75 million people in 2030 and a staggering 130 million people in 2050. Today, treating patients with Alzheimer's disease around the world costs about $600 billion which is equivalent to 1% of the entire world's gross domestic product. This number is expected to dramatically increase in the future as well, especially if no breakthrough treatment is invented and released on the market.
As of today, there is no cure for Alzheimer's disease or any other form of dementia. There are some drugs that can slow down the progression and reduce some symptoms but the reality is that no new Alzheimer's drug has been released in 18 years (Galantamine, Janssen Pharmaceutical Inc., 2000) and the current treatment options have a very modest effect at best.
If we cannot discern the mechanisms underlying Alzheimer's disease progression and find a new effective way of treating the disease, we are looking at a bleak future filled with old people unable to comprehend, understand or remember who their daughters and sons are. Looking at where we are today, both from a humanistic and a socioeconomic perspective, it becomes clear that the need for new innovative drugs treating patients suffering from Alzheimer's disease and other forms of dementia has never been higher and more urgent than as of now. We just cannot afford to lose to this disease.
ReceptorPharma has the goal to develop new Alzheimer's drugs through a completely new pathway and mechanism. We are utilizing the very latest research and findings regarding disease-coupled genes and combining it with the usage of one of the most well-studied drug target protein families, G Protein-Coupled Receptors (GPCRs) - drug targets in 35% of modern pharmaceuticals. This novel approach to create a new generation of Alzheimer's disease drugs that act through GPCRs is our competitive advantage and where our competences shine. Our approach will lead to a new class of small molecule γ-secretase inhibitors (GSIs) with no effect on Notch processing, thus circumventing one of the major obstacles that previous GSIs have been unable to overcome.
In addition to Alzheimer's disease, our approach will allow for the development of new drugs for Parkinson's disease and certain types of cancer through similar mechanisms using disease-coupled GPCRs as drug targets.
SmiLe Incubator is a business incubator located at Medicon Village in Lund, Sweden. We help entrepreneurs and early stage companies in the life sciences develop and commercialize new ideas.
With actors such as the European Spallation Source (ESS), the BioMedical Centre (BMC) and the Max IV Laboratory close by, Medicon Village is part of a unique cluster of research and development capability.